| ROCHE I |
| Date/Time | / |
| Chg. / Chg.(%) | - / |
| Bid | - |
| Ask | - |
| Open | - |
| Previous Close | - |
| High | - |
| Low | - |
| Volume [CHF] | - |
| Volume [Units] | |
| Price fixings | |
| ISIN | CH0012032113 |
| Security | RO |
| Exchange | SIX Swiss Exchange |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| Lang & Schwa.. | 241.16 |  |
|
| SIX Swiss Ex.. | 271.00 | |
38,460 |
| TradeGate | 241.600 | |
22,863 |
| Cboe Europe .. | 271.40 | |
1,503 |
| London Inter.. | 269.15 | |
902 |
| Frankfurt | 241.800 |  |
715 |
| Cboe Europe .. | 271.00 | |
340 |
| Xetra | 238.20 | |
233 |
| Düsseldorf | 241.60 | |
120 |
| Turquoise | 271.50 | |
75 |
| Hannover | 241.20 | |
60 |
| gettex | 242.200 | |
30 |
| Stuttgart | 242.000 | |
30 |
| Berlin | 242.00 | |
20 |
| München | 238.80 | |
0 |
| Hamburg | 239.00 | |
0 |
| Nasdaq Other.. | 265.3000 | 72 |
News
- Roche announces FDA approval for Venclexta plus Gazyva for people with previously untreated chronic lymphocytic leukaemia
05/16/2019 / 07:03 - GlobeNewswire - Roche's personalised medicine entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions in children and adolescents
05/16/2019 / 07:00 - GlobeNewswire - New Roche test aids clinicians in accelerating tuberculosis diagnosis and treatment by detecting antimicrobial resistance within the world's leading cause of infectious disease deaths
05/14/2019 / 07:03 - GlobeNewswire - Roche and Spark Therapeutics, Inc. announce expected refiling date of Premerger Notification and Report Forms under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc.
05/14/2019 / 07:00 - GlobeNewswire - Roche to present new data highlighting comprehensive approach to cancer care at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
05/10/2019 / 07:00 - GlobeNewswire
Personal area
Real-timeClick on 
to activate push quotes.
to activate push quotes.